Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients

Background Drug resistance significantly weakens the efficacy of cancer treatment, and the BIM (also known as the BCL2L11 gene) deletion polymorphism has been identified as a potential biomarker for drug resistance. In this retrospective study, we included a total of 290 patients with advanced non‐s...

Full description

Saved in:
Bibliographic Details
Published in:Thoracic cancer 2014-11, Vol.5 (6), p.509-516
Main Authors: Zhong, Jia, Li, Zheng-Xiang, Zhao, Jun, Duan, Jian-Chun, Bai, Hua, An, Tong-Tong, Yang, Xiao-Dan, Wang, Jie
Format: Article
Language:English
Subjects:
Chemotherapy
Drug resistance
EGFR tyrosine kinase inhibitor
Genes
Kinases
Lung cancer
Mutation
non-small cell lung cancer
Original
polymorphism
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Drug resistance significantly weakens the efficacy of cancer treatment, and the BIM (also known as the BCL2L11 gene) deletion polymorphism has been identified as a potential biomarker for drug resistance. In this retrospective study, we included a total of 290 patients with advanced non‐small cell lung cancer (NSCLC) who received treatment with epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) and chemotherapy. Methods The BIM deletion polymorphism of each patient was detected by polymerase chain reaction. EGFR mutations were detected by denaturing high‐performance liquid chromatography methods and the amplification refractory mutation system. Results The BIM deletion polymorphism was detected in 45/290 (15.5%) Chinese NSCLC patients. No associations were observed between the BIM deletion and clinic‐pathologic characteristics of patients. The BIM deletion polymorphism was predictive of shorter progression‐free survival in Chinese patients with EGFR‐mutant adenocarcinoma and who were treated with EGFR‐TKIs (7.30 vs. 9.53 months, P = 0.034). Additionally, we found that the BIM deletion polymorphism was an effective predictor of short progression‐free survival in individuals with EGFR‐mutant NSCLC and treated with chemotherapy containing pemetrexed (3.32 vs. 5.30, P = 0.012) or second‐/beyond‐line chemotherapy containing taxanes (1.53 vs. 2.61 months, P = 0.025). The BIM deletion was not correlated with overall survival. Conclusion The BIM deletion polymorphism occurs in 15.5% of Chinese NSCLC patients, and is a biomarker for resistance to TKIs and chemotherapy. However, BIM deletion was not a decisive factor in overall survival.
ISSN:1759-7706
1759-7714
DOI:10.1111/1759-7714.12119